New laboratory targeting cardiovascular breakthroughs

A national laboratory specializing in cardiovascular diseases has been launched in Shenzhen, with the aim of expediting the industrialization of innovative achievements in the field.

The laboratory is a collaboration between Baheal Pharma Group and two hospitals affiliated with the Chinese Academy of Medical Sciences: Fuwai Hospital and Fuwai Shenzhen Hospital.

The new laboratory's research directions will include disease warning and prediction, original theoretical targets discovery and drug development, and domestic medical device research and development.

Baheal Pharma Group said the laboratory has established a comprehensive innovative system covering activities from research to industrial implementation.

A report from the National Center for Cardiovascular Diseases showed that the number of cardiovascular disease patients in China has reached 330 million and is continuing to rise.

Baheal said the laboratory will also provide support and industrial resource backing for the development of cardiovascular disease diagnosis and treatment.